Table.
COVID-19 vaccine clinical trials
| Vaccine type | Location | Trial number | |
|---|---|---|---|
| Phase 1 trials only | |||
| Inovio | DNA (INO-4800) | USA | NCT04336410 |
| Genexine | DNA (GX-19) | South Korea | NCT04445389 |
| Academy of Military Sciences; Suzhou Abogen Biosciences; Walvax Biotechnology | mRNA (ARCoV) | China | .. |
| ReiThera; Lazzaro Spallanzani National Institute for Infectious Diseases | Gorilla adenovirus vector (GRAd-CoV2) | Italy | NCT04528641 |
| Clover Pharmaceuticals; Dynavax Technologies | Protein (SCB-2019) | .. | NCT04405908 |
| Vaxine | Protein | Australia | NCT04453852 |
| Medicago; GSK; Dynavax Technologies | Virus-like particle | USA | NCT04450004 |
| University of Queensland; CSL | Proteins | Australia | NCT04495933 |
| Kentucky Bioprocessing | Plant | USA | NCT04473690 |
| Medigen; Dynavax Technologies | Protein (MVC-COV1901) | Taiwan | NCT04487210 |
| Adimmune | Protein (AdimrSC-2f) | Taiwan | NCT04522089 |
| West China Hospital of Sichuan University | Protein | China | NCT04470609 |
| Sanofi; GSK | Protein | .. | NCT04537208 |
| Merck; Pasteur Institute | Measles vector | France | NCT04497298 |
| Research Institute for Biological Safety Problems | Inactivated virus (QazCovid) | Kazakhstan | NCT04530357 |
| Themis; Merck; University of Pittsburgh Center for Vaccine Research | Vesicular stomatitis virus-vectored (COVID-19–101) | Belgium; France | NCT04497298 |
| Symvivo | Oral (bacTRL-Spike) | USA; Canada | NCT04334980 |
| Phase 1 and phase 2 trials | |||
| Imperial College London; Morningside Ventures | Self-amplifying RNA | UK | .. |
| AnGes; Osaka University; Takara Bio | DNA (AG0302-COVID19) | Japan | NCT0452708; NCT04463472 |
| Arcturus; Duke-NUS Medical School | mRNA (LUNAR-COV19) | Singapore | NCT04480957 |
| Johnson & Johnson; Beth Israel Deaconess Medical Center | Adenovirus serotype 26 vector (Ad26.COV2-S) | USA | NCT04436276 |
| Novavax | Nanoparticle (NVX-CoV2373) | USA; South Africa | NCT04533399 |
| Finlay Vaccine Institute | Protein (Soberana 1) | Cuba | .. |
| Vector Institute | Peptide (EpiVacCorona) | Russia | NCT04527575 |
| Bharat Biotech; Indian Council of Medical Research; National Institute of Virology | Inactivated virus (Covaxin) | India | NCT04471519 |
| Anhui Zhifei Longcom Biopharmaceutical; Institute of Microbiology of the Chinese Academy of Sciences | Protein | China | .. |
| Zydus Cadila | DNA (ZyCoV-D) | India | .. |
| Curevac | mRNA (CVnCoV) | Germany, Belgium | NCT04449276, NCT04515147 |
| Phase 3 trials | |||
| AstraZeneca; University of Oxford (30 000 participants) | Chimpanzee adenovirus (ChAdOx1/AXD1222) | UK; India; Brazil, South Africa; USA | NCT04516746 |
| Moderna; National Institutes of Health (30 000 participants) | RNA (mRNA-1273) | USA | NCT04470427 |
| Pfizer; BioNTech (44 000 participants) | RNA (BNT162b1 and BNT162b2) | USA | NCT04368728 |
| The Janssen Pharmaceutical Companies of Johnson & Johnson (60 000 participants) | Adenovirus serotype 26 vector (Ad26.COV2.S) | USA; Argentina; Brazil; Chile; Columbia; Mexico; Peru; Philippines; South Africa; Ukraine | NCT04505722 |
| The Gamaleya National Research Centre for Epidemiology and Microbiology; Academy of Military Medical Sciences (40 000 participants) | Adenovirus serotype 5 vector and adenovirus serotype 26 vector (Sputnik V) | Russia | NCT04530396 |
| CanSino Biologics; Academy of Military Medical Sciences (40 000 participants) | Adenovirus serotype 5 vector (Ad5CoV) | China; Pakistan | NCT04526990 |
| Sinovac Biotech (9000 participants) | Inactivated virus (CoronaVac) | Brazil; Indonesia | .. |
| Sinopharm; Wuhan Institute of Biological Products (21 000 participants) | Inactivated virus | The United Arab Emirates; Bahrain; Peru; Morocco; Argentina; Jordan | .. |
| Sinopharm; Beijing Institute of Biological Products (5000 participants) | Inactivated virus (BBIBP-CorV) | The United Arab Emirates | .. |